Circulating n-3 fatty acid levels and total and cause-specific mortality: A de novo pooled analysis from 17 prospective studies
Published version
Peer-reviewed
Repository URI
Repository DOI
Change log
Authors
Abstract
The health effects of omega-3 fatty acids (n-3 FAs) have been controversial. A de novo pooled analysis was conducted with 17 prospective cohort studies examining the associations between blood n-3 FAs levels and risk for all-cause mortality. Over a median of 15 years of follow-up, 15,720 deaths occurred among 42,466 individuals. After adjustment for relevant risk factors, risk for death from all causes was significantly lower (by 15-18%) in the highest vs the lowest quintile for circulating long chain (20-22 carbon) n-3 FAs, but not for the 18-carbon n-3 FA. These novel findings suggest that higher circulating levels of marine n-3 PUFA may be associated with a lower risk of premature death.
Description
Keywords
Journal Title
Nature Communications
Conference Name
Journal ISSN
2041-1723
Volume Title
Publisher
Nature Research
Publisher DOI
Publisher URL
Rights and licensing
Except where otherwised noted, this item's license is described as Attribution 4.0 International
Sponsorship
Medical Research Council (MC_UU_12015/5)
MRC (MC_UU_00006/3)
Medical Research Council (MC_UU_12015/1)
MRC (MC_UU_00006/1)
Cambridge University Hospitals NHS Foundation Trust (CUH) (146281)
Department of Health (via National Institute for Health Research (NIHR)) (NIHR202397)
MRC (MC_UU_00006/3)
Medical Research Council (MC_UU_12015/1)
MRC (MC_UU_00006/1)
Cambridge University Hospitals NHS Foundation Trust (CUH) (146281)
Department of Health (via National Institute for Health Research (NIHR)) (NIHR202397)
The EPIC Norfolk study (DOI 10.22025/2019.10.105.00004) has received funding from the Medical Research Council (MR/N003284/1 and MC-UU_12015/1) and Cancer Research UK (C864/A14136). NJW, NGF, and FI were supported by the Medical Research Council Epidemiology Unit core funding [MC_UU_12015/1 and MC_UU_12015/5]. NJW and NGF acknowledge support from the National Institute for Health Research Cambridge Biomedical Research Centre [IS-BRC-1215-20014] and NJW is an NIHR Senior Investigator.

